On August 21, 2025, Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSinoBIO, was featured in an exclusive live interview on Bloomberg TV — the company’s second appearance on the global financial media platform this year. Dr. Yu highlighted CanSinoBIO’s first-half results, its focus on high-quality innovation, and the international rollout of its products, emphasizing the company’s confidence and progress in driving vaccine development and expanding its presence worldwide.

Robust Results Driven by Strong Performance of High-Quality Innovative Products

Q1：What’s your opinion on CanSinoBIO's performance in the first half of 2025?

In the first half of 2025, CanSinoBIO reported revenue of RMB 382 million, up 26% year on year, driven by the strong market performance of its quadrivalent meningococcal conjugate vaccine, Menhycia^® (MCV4). Sales of the company’s meningococcal vaccine portfolio exceeded RMB 364 million, representing year-on-year growth of over 38%. These results highlight the increasing market acceptance of high-quality innovative vaccines.

Innovative vaccines better adapted to domestic needs are set to enter the market

Q2：CanSinoBIO’s 13-valent pneumococcal conjugate vaccine, iPneucia^®（PCV13i）, received official approval this year. What is your outlook on the market potential of this product?

Through improved technological upgrades, this vaccine now covers serotypes that better match the prevalence of pneumococcal disease among children in China, making it more aligned with domestic market needs. iPneucia^® is expected to complete its first batch of deliveries in the coming months, with plans to expand coverage across a larger domestic market next year. At the same time, overseas markets are also part of our strategic rollout.

The core competitiveness of iPneucia^® lies in its innovative design and its enhanced protection against serotypes commonly found in China. We believe this product will be widely embraced by the market.

Leading Global Expansion with Innovative Products

Q3：CanSinoBIO has been expanding its presence in overseas markets. Could you share your plans in this regard?

Entering international markets requires time, as it involves multiple steps, including registration, clinical trials, and regulatory approvals, etc. We are working with partners in several countries to advance the global rollout of our products. For example, in 2023, CanSinoBIO’s Kweisha^® Inhaled COVID-19 Vaccine, the world’s first inhaled recombinant COVID-19 vaccine, received emergency use authorization from Indonesia’s BPOM. In 2024, Menhycia^® was also approved in Indonesia. The product is expected to be exported in the second half of this year, with plans to launch in additional countries over the coming year.

Pioneering Domestic Product Development, Creating More Growth Opportunities

Q4：How do you envision the company’s development over the next three to five years?

In the first half of this year, our net loss narrowed significantly, by over 94% year on year, laying a solid foundation for stable growth throughout the year. Over the next three to five years, we plan to launch multiple innovative products developed in China, which hold significant market potential.

For example, to date, the DTcP vaccine for infants (below 2 years old) has been included in the NMPA‘s priority review list, and the Tdcp vaccine for adolescents & adults has completed enrollment for its Phase III clinical trial, aiming to provide coverage across the full life cycle. A series of high-quality innovative products is expected to fill market gaps and create new growth opportunities.